BIOMAT Database Logo BIOMAT Database Logo

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects. 2021

Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.

OBJECTIVE Safety, tolerability and pharmacokinetics of single and multiple ascending doses (SADs/MADs) of benfotiamine were assessed after oral administration in two randomized, double-blind, placebo-controlled, phase I trials. METHODS Healthy subjects were sequentially enrolled into one of five SAD (150-1200 mg) or three MAD (150, 300 or 600 mg) cohorts. In SAD study, each cohort of 12 subjects (n = 10, active; n = 2, placebo) were administrated once-daily doses. In MAD study, each cohort of 16 subjects (n = 12, active; n = 4, placebo) were administrated once-daily on day 1 and twice-daily on day 4-9, followed by a single morning dose on day 10. RESULTS In the SAD study, the median time to reach maximum concentration (Tmax) arrived 1.0 to 2.0 h for thiamine (TM), 3.5 to 8.0 h for thiamine monophosphate (TMP), and 8.0 to 24.0 h for thiamine diphosphate (TDP) after administration of benfotiamine. The area under concentration-time curve from 0 to last measurable concentration (AUC0-t) or maximum observed concentration (Cmax) of TM, TMP, and TDP was less or more dose proportional over the single dose studied except Cmax of TM. Food consumption did not increase the level of TM and TDP at baseline. TM exhibited a relatively long elimination half-life (t1/2) in all doses studied, resulting in accumulation ratio (Rac) of 1.96 to 2.11 and accumulation ratio based on Cmax (Rac, Cmax) of 1.60 to 1.88 following 7 days of multiple dosing. Comparable accumulation results were also obtained for TDP after multiple dosing. The incidence and severity of adverse events (AEs) were similar between benfotiamine and placebo. The commonly reported drug-related AEs were increased ALT and urinary WBC. CONCLUSIONS Both SAD and MAD studies of benfotiamine in healthy subjects were safe and well tolerated. TM and TDP exhibited moderate accumulation on repeated administration of benfotiamine.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013831 Thiamine 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2- hydroxyethyl)-4-methylthiazolium chloride. Aneurin,Vitamin B 1,Thiamin,Thiamine Mononitrate,Vitamin B1,Mononitrate, Thiamine

Related Publications

Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
November 2006, Journal of clinical pharmacology,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects.
February 2019, Clinical pharmacology in drug development,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
June 1997, Cephalalgia : an international journal of headache,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects.
January 2021, Clinical drug investigation,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects.
January 2022, Drug design, development and therapy,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.
March 2009, British journal of clinical pharmacology,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants.
March 2024, Clinical pharmacology in drug development,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
February 2008, Clinical pharmacology and therapeutics,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.
October 2004, Diagnostic microbiology and infectious disease,
Lei Sheng, and Wei Cao, and Pingping Lin, and Weili Chen, and Hongrong Xu, and Chunjiu Zhong, and Fei Yuan, and Hanjing Chen, and Hui Li, and Chao Liu, and Mengjie Yang, and Xuening Li
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
October 2020, European journal of drug metabolism and pharmacokinetics,
Copied contents to your clipboard!